C-reactive protein and colorectal cancer risk: A systematic review of prospective studies

✍ Scribed by Konstantinos K. Tsilidis; Casey Branchini; Eliseo Guallar; Kathy J. Helzlsouer; Thomas P. Erlinger; Elizabeth A. Platz

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: French
• Weight: 295 KB
• Volume: 123
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.23606

✦ Synopsis

Abstract

C‐reactive protein is a sensitive but nonspecific systemic marker of inflammation. Several prospective studies have investigated the association of prediagnostic circulating C‐reactive protein concentrations with the development of colorectal cancer, but the results have been inconsistent. We performed a systematic review of prospective studies of the association between prediagnostic measurements of circulating high‐sensitivity C‐reactive protein and development of invasive colorectal cancer. Authors of original studies were contacted to acquire uniform data. We combined relative risks (RR) for colorectal cancer associated with a one unit change in natural logarithm‐transformed high‐sensitivity C‐reactive protein using inverse variance weighted random effects models. We identified eight eligible studies, which included 1,159 colorectal cancer cases and 37,986 controls. The summary RR per one unit change in natural log‐transformed high‐sensitivity C‐reactive protein was 1.12 (95% confidence intervals [CI], 1.01–1.25) for colorectal cancer, 1.13 (95% CI, 1.00–1.27) for colon cancer, and 1.06 (95% CI, 0.86–1.30) for rectal cancer. The association was stronger in men (RR, 1.18; 95% CI, 1.04–1.34) compared to women (RR, 1.09; 95% CI, 0.93–1.27) but this difference was sensitive to the findings from a single study. Prediagnostic high‐sensitivity C‐reactive protein concentrations were weakly associated with an increased risk for colorectal cancer. More work is needed to understand the extent to which circulating high‐sensitivity C‐reactive protein or other blood inflammatory markers are related to colonic inflammation. © 2008 Wiley‐Liss, Inc.